Assessing the use of navigators for improvement of patient adherence to onabotulinumtoxinA

Video

“We really felt that this was an important question to ask because we know that OAB therapy adherence is associated with improvements in urinary symptoms, quality of life, and decreased OAB-related health care costs,” says Ekene Enemchukwu, MD, MPH.

In this video, Ekene Enemchukwu, MD, MPH, discusses the background of the study, “Identifying navigator impact on utilization of onabotulinumtoxina as a 3rd line treatment in overactive bladder: A retrospective database study in the United States” This study was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting. Enemchukwu is a pelvic reconstruction surgeon at Stanford Health Care, and an assistant professor of urology and obstetrics and gynecology at the Stanford University School of Medicine in California.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Expert on OAB
Expert on OAB
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Katherine Shapiro, MD, answers a question during a Zoom video interview
Experts on OAB
Expert on OAB
Expert on OAB
Expert on OAB
Related Content
© 2023 MJH Life Sciences

All rights reserved.